GlassScriptPhysician profile
Sheena Shah
NPI 1548711690
$4,021.65
in general payments reported to CMS, 2019-2025
29 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $841 · 2022: $974 · 2023: $847 · 2024: $878 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,112.52 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $908.24 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $296.21 | 2021-2023 | Belsomra, Steglatro |
| Bausch Health US, LLC | $283.51 | 2021-2024 | Aplenzin |
| Pfizer INC. | $215.78 | 2021-2025 | |
| Abbott Laboratories | $201.19 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $184.80 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $107.41 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Ge Healthcare | $76.79 | 2021-2023 | |
| Insulet Corporation | $66.77 | 2025 | Omnipod |
| Amarin Pharma, INC. | $54.98 | 2021 | |
| Althera Pharmaceuticals LLC | $46.60 | 2021-2022 | |
| Allergan, INC. | $45.68 | 2021-2022 | |
| Eisai INC. | $44.63 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.66 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $38.74 | 2023 | |
| Glaxosmithkline, LLC. | $32.08 | 2023-2025 | Shingrix, Arexvy |
| Dexcom, INC. | $31.14 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $30.22 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.19 | 2022 | |
| Medtronic, INC. | $26.33 | 2022 | |
| Arbor Pharmaceuticals, INC. | $25.98 | 2021 | |
| Vistapharm, INC. | $25.14 | 2021 | |
| Astellas Pharma US INC | $24.90 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $15.26 | 2024 | Breztri |
| Daiichi Sankyo INC. | $14.65 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.00 | 2023 | Horizant |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2022 | |
| Esperion Therapeutics, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.